Cited by 278Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors.

Open access

Blankenhorn, D H, Alaupovic, P, Wickham, E, Chin, H P, Azen, S P·1990·Circulation

DOI 10.1161/01.cir.81.2.470

Open this paper in CoChat — free account Open PDF

Abstract

A within-group risk factor analysis was conducted to predict angiographic change in the Cholesterol Lowering Atherosclerosis Study, a randomized, placebo-controlled trial of colestipol plus niacin therapy in men with previous coronary bypass surgery. Global angiographic change, including both native coronary arteries and bypass grafts after 2 treatment years, was the end point. Risk factors included on-trial clinical measures, plasma lipids, lipoproteins, and apolipoproteins. Univariate analysis indicated that risk factors previously observed by others in epidemiologic investigation of ischemic heart disease--total cholesterol, LDL cholesterol, non-HDL cholesterol, triglycerides, apolipoprotein B, and diastolic blood pressure--had significant effects in the placebo-treated group. Univariate analysis indicated significant effects of apolipoprotein C-III in drug- and placebo-treated groups. Multivariate analysis indicated the predominant risk factor predicting the probability of global coronary progression was non-HDL cholesterol in placebo-treated subjects and the content of apolipoprotein C-III in high density lipoproteins of drug-treated subjects. Both drug- and placebo-treated group findings point to an important role for triglyceride-rich lipoproteins in progression and regression of human atherosclerosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/01.cir.81.2.470

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747
Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions
Burstein, M., Scholnick, H. R., & Morfin, R. F. (1970) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42943-8 · Cited by 2,500
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts
Blankenhorn, D. H. (1987) · JAMA · doi:10.1001/jama.1987.03390230069027 · Cited by 1,654
Self-citation
Sur un dosage rapide du cholesterol lié aux α-et aux β-lipoprotéines du sérum
Burstein, M., & Samaille, J. (1960) · Clinica Chimica Acta · doi:10.1016/0009-8981(60)90075-9 · Cited by 620
Diet, Lipoproteins, and the Progression of Coronary Atherosclerosis
Arntzenius, A. C., Kromhout, D., Barth, J. D., Reiber, J. H. C., Bruschke, A. V. G., Buis, B., van Gent, C. M., Kempen-Voogd, N., Strikwerda, S., & van der Velde, E. A. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503283121301 · Cited by 498

Flagged first, then by citations

Show all 32 references

Sorted by citations

Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events
Hodis, H. N., Mack, W. J., LaBree, L., Selzer, R. H., Liu, C.-R., Liu, C.-H., & Azen, S. P. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-4-199802150-00002 · Cited by 1,217
Self-citation
Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state
Patsch, J. R., Miesenböck, G., Hopferwieser, T., Mühlberger, V, Knapp, E., Dunn, J. K., Gotto, A. M., & Patsch, W. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.11.1336 · Cited by 1,122
Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events
Robins, S. J., Collins, D. E., Wittes, J. T., Papademetriou, V., DEEDWANIA, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., WEXLER, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 917
Metabolic origins and clinical significance of LDL heterogeneity
Berneis, K. K., & Krauss, R. M. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200004-jlr200 · Cited by 896
Fasting Triglycerides, High-Density Lipoprotein, and Risk of Myocardial Infarction
Gaziano, J. M., Hennekens, C. H., O’Donnell, C. J., Breslow, J. L., & Buring, J. E. (1997) · Circulation · doi:10.1161/01.cir.96.8.2520 · Cited by 602
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490
Self-citation
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
Apolipoprotein B and apolipoprotein A‐I: risk indicators of coronary heart disease and targets for lipid‐modifying therapy
Walldius, G., & Jungner, I. (2004) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01276.x · Cited by 395
Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemfibrozil After Coronary Bypass Surgery in Men With Low Levels of HDL Cholesterol
Frick, M. H., Syvänne, M., Nieminen, M. S., Kauma, H., Majahalme, S. K., Virtanen, V., Kesäniemi, Y. A., Pasternack, A. I., & Taskinen, M. (1997) · Circulation · doi:10.1161/01.cir.96.7.2137 · Cited by 389
HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men.
Salonen, J. T., Salonen, R. M., Seppänen, K., Rauramaa, R., & Tuomilehto, J. O. (1991) · Circulation · doi:10.1161/01.cir.84.1.129 · Cited by 360
Lipoprotein Metabolism and Renal Failure
Attman, P., Samuelsson, O. G., & Alaupovic, P. (1993) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80030-8 · Cited by 356
Self-citation
Atherosclerosis and arteriosclerosis in chronic renal failure
London, G. M., & Drüeke, T. B. (1997) · Kidney International · doi:10.1038/ki.1997.233 · Cited by 351
Selective Retention of VLDL, IDL, and LDL in the Arterial Intima of Genetically Hyperlipidemic Rabbits In Vivo: Molecular Size as a Determinant of Fractional Loss From the Intima–Inner Media
Nordestgaard, B. G., Wootton, R., & Lewis, B. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.4.534 · Cited by 334
Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
Hodis, H. N., Mack, W. J., Azen, S. P., Alaupovic, P., Pogoda, J. M., LaBree, L., Hemphill, L., Kramsch, D. M., & Blankenhorn, D. H. (1994) · Circulation · doi:10.1161/01.cir.90.1.42 · Cited by 321
Self-citation
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260
Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins
Zilversmit, D. B. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.1.153 · Cited by 260
New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism
Ginsberg, H. N. (2002) · Circulation · doi:10.1161/01.cir.0000035280.64322.31 · Cited by 255
Coronary bypass graft fate: Long-term angiographic study
FitzGibbon, G. M., Leach, A. J., Kafka, H. P., & Keon, W. J. (1991) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(91)90834-v · Cited by 234
Atherogenicity of Triglyceride-Rich Lipoproteins
Krauss, R. M. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00032-0 · Cited by 227
Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis.
Salonen, J. T., Salonen, R. M., Seppänen, K., Kantola, M., Suntioinen, S., & Korpela, H. (1991) · BMJ · doi:10.1136/bmj.302.6779.756 · Cited by 205
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
Fruchart‐Najib, J., Baugé, E., Niculescu, L. S., Pham, T., Thomas, B., Rommens, C., Majd, Z., Brewer, B., Pennacchio, L. A., & Fruchart, J. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.05.003 · Cited by 203
Apolipoprotein CIII in Apolipoprotein B Lipoproteins Enhances the Adhesion of Human Monocytic Cells to Endothelial Cells
Kawakami, A., Aikawa, M., Libby, P., Alcaide, P., Luscinskas, F. W., & Sacks, F. M. (2006) · Circulation · doi:10.1161/circulationaha.105.591743 · Cited by 206
The Influence of Diet on the Appearance of New Lesions in Human Coronary Arteries
Blankenhorn, D. H. (1990) · JAMA · doi:10.1001/jama.1990.03440120068039 · Cited by 191
Self-citation
Laboratory Assessment of HDL Heterogeneity and Function
Movva, R., & Rader, D. J. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.101923 · Cited by 190
Task force 1. Pathogenesis of coronary disease: The biologic role of risk factors
Fuster, V., Gotto, A. M., Libby, P., Loscalzo, J., & McGill, H. C. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)00014-9 · Cited by 190
The Role of Triglyceride-Rich Lipoprotein Families in the Progression of Atherosclerotic Lesions as Determined by Sequential Coronary Angiography From a Controlled Clinical Trial
Alaupovic, P., Mack, W. J., Knight‐Gibson, C., & Hodis, H. N. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.4.715 · Cited by 184
Self-citation
Lipoprotein Subclasses in the Monitored Atherosclerosis Regression Study (MARS)
Mack, W. J., Krauss, R. M., & Hodis, H. N. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.5.697 · Cited by 173
Effects of colestipol-niacin therapy on human femoral atherosclerosis.
Blankenhorn, D. H., Azen, S. P., Crawford, D. W., Nessim, S., Sanmarco, M. E., Selzer, R. H., Shircore, A. M., & Wickham, E. (1991) · Circulation · doi:10.1161/01.cir.83.2.438 · Cited by 172
Self-citation
A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity
Seshadri, P., Iqbal, N., Stern, L., Williams, M., Chicano, K. L., Daily, D. A., McGrory, J., Gracely, E. J., Rader, D. J., & Samaha, F. F. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.04.009 · Cited by 169
Minimum heart rate and coronary atherosclerosis: Independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age
Perski, A., Olsson, G., Landou, C., Fairé, U. D., Theorell, T., & Hamsten, A. (1992) · American Heart Journal · doi:10.1016/0002-8703(92)90497-j · Cited by 166
Predominance of Dense Low-Density Lipoprotein Particles Predicts Angiographic Benefit of Therapy in the Stanford Coronary Risk Intervention Project
Miller, B. D., Alderman, E. L., Haskell, W. L., Fair, J. M., & Krauss, R. M. (1996) · Circulation · doi:10.1161/01.cir.94.9.2146 · Cited by 161
Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease
Brewer, H. B. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00308-2 · Cited by 158
Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins
Cohn, J. S., Marcoux, C., & Davignon, J. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.10.2474 · Cited by 156
Coronary Artery Disease in Heterozygous Familial Hypercholesterolemia Patients With the Same LDL Receptor Gene Mutation
Ferrières, J., Lambert, J., Lussier‐Cacan, S., & Davignon, J. (1995) · Circulation · doi:10.1161/01.cir.92.3.290 · Cited by 155
Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen
Harjai, K. J. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-5-199909070-00009 · Cited by 150
Triglyceride-Rich Lipoprotein Remnant Particles and Risk of Atherosclerosis
Hodis, H. N. (1999) · Circulation · doi:10.1161/01.cir.99.22.2852 · Cited by 149
Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS)
Watts, G. F., Mandalia, S., Brunt, J. N. H., Slavin, B. M., COLTART, D. J., & Lewis, B. (1993) · Metabolism · doi:10.1016/0026-0495(93)90199-x · Cited by 146
Apolipoprotein C‐III as a Potential Modulator of the Association Between HDL‐Cholesterol and Incident Coronary Heart Disease
Jensen, M. K., Rimm, E. B., Furtado, J. D., & Sacks, F. M. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.111.000232 · Cited by 142
Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease
Olivieri, O., Bassi, A., Stranieri, C., Trabetti, E., Martinelli, N., Pizzolo, F., Girelli, D., Friso, S., Pignatti, P. F., & Corrocher, R. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300253-jlr200 · Cited by 139
Impact of Statin Use on Outcomes After Coronary Artery Bypass Graft Surgery
Kulik, A., Brookhart, M. A., Levin, R., Ruel, M., Solomon, D. H., & Choudhry, N. K. (2008) · Circulation · doi:10.1161/circulationaha.108.799445 · Cited by 137
Low-Density Lipoproteins Containing Apolipoprotein C-III and the Risk of Coronary Heart Disease
Mendivil, C. O., Rimm, E. B., Furtado, J., Chiuve, S. E., & Sacks, F. M. (2011) · Circulation · doi:10.1161/circulationaha.111.056986 · Cited by 136
Triglycerides and Coronary Risk in Women and the Elderly
LaRosa, J. C. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440300051004 · Cited by 136
Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders
Onat, A., Hergenç, G., Sansoy, V., Fobker, M., Ceyhan, K., Toprak, S., & Assmann, G. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00025-x · Cited by 134
Predicting requirement change propagation, using higher order design structure matrices: an industry case study
Morkos, B. W., Shankar, P., & Summers, J. D. (2012) · Journal of Engineering Design · doi:10.1080/09544828.2012.662273 · Cited by 129
Impaired chylomicron remnant clearance in familial combined hyperlipidemia.
Cabezas, M. C., de Bruin, T. W. A., Jansen, H., Kock, L. A., Kortlandt, W., & Erkelens, D. W. (1993) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.13.6.804 · Cited by 123
Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study
Russo, G. T., Meigs, J. B., Cupples, L. A., Demissie, S., Otvos, J. D., Wilson, P. W. F., Lahoz, C., Cucinotta, D., Couture, P., Mallory, T., et al. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00409-9 · Cited by 125
The Asp 9 Asn Mutation in the Lipoprotein Lipase Gene Is Associated With Increased Progression of Coronary Atherosclerosis
Jukema, J. W., Boven, A. J. V., Groenemeijer, B. E., Zwinderman, A. H., Reiber, J. H. C., Bruschke, A. V. G., Henneman, J. A., Molhoek, G. P., Bruin, T., Jansen, H., et al. (1996) · Circulation · doi:10.1161/01.cir.94.8.1913 · Cited by 123
Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases
Koba, S., Hirano, T., Ito, Y., Tsunoda, F., Yokota, Y., Ban, Y., Iso, Y., Suzuki, H., & Katagiri, T. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.12.002 · Cited by 121
Beyond LDL Cholesterol Reduction
Superko, H. R. (1996) · Circulation · doi:10.1161/01.cir.94.10.2351 · Cited by 119
Triglycerides: a risk factor for coronary heart disease
Davignon, J., & Cohn, J. S. (1996) · Atherosclerosis · doi:10.1016/0021-9150(96)05858-3 · Cited by 116
Apolipoprotein C-III
Kohan, A. B. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000136 · Cited by 116
Gene-diet interaction in determining plasma lipid response to dietary intervention
Ordovás, J. M., López‐Miranda, J., Mata, P., Pérez‐Jiménez, F., Lichtenstein, A. H., & Schaefer, E. J. (1995) · Atherosclerosis · doi:10.1016/0021-9150(95)90069-1 · Cited by 115
Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions
Fredenrich, A., Giroux, L.-M., Tremblay, M., Krimbou, L., Davignon, J., & Cohn, J. S. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37424-1 · Cited by 115
[2] Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins
Alaupovic, P. (1996) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(96)63004-3 · Cited by 109
Self-citation
High-Density Lipoprotein Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four Cohorts
Jensen, M. K., Aroner, S. A., Mukamal, K. J., Furtado, J. D., Post, W. S., Tsai, M. Y., Tjønneland, A. M., Polak, J. F., Rimm, E. B., Overvad, K., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.031276 · Cited by 109
Metabolic abnormalities: triglyceride and low-density lipoprotein
Krauss, R. M., & Siri, P. W. (2004) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.03.016 · Cited by 102
Small LDL-Cholesterol is Superior to LDL-Cholesterol for Determining Severe Coronary Atherosclerosis
Koba, S., Yokota, Y., Hirano, T., Ito, Y., Ban, Y., Tsunoda, F., Sato, T., Shoji, M., Suzuki, H., Geshi, E., et al. (2008) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e572 · Cited by 102
Lipid and apolipoprotein abnormalities in hirsute women
Wild, R. A., Alaupovic, P., & Parker, I. J. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(11)90605-x · Cited by 102
Self-citation
Apolipoproteins C–III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur 'Infarctus du Myocarde
Luc, G., Fievet, C., Arveiler, D., Evans, A. E., Bard, J. M., Cambien, F., Fruchart, J. C., & Ducimetiere, P. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37594-5 · Cited by 114
Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure
Sentı́, M., Romero, R., Pedro‐Botet, J., Pelegrí, A., Nogués, X., & Rubiés-Prat, J. (1992) · Kidney International · doi:10.1038/ki.1992.204 · Cited by 99
The genetics of serum lipid responsiveness to dietary interventions
Ordovás, J. M. (1999) · Proceedings of The Nutrition Society · doi:10.1079/pns19990023 · Cited by 95
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
Ferrari, R., Aguíar, C., Alegría, E., Bonadonna, R. C., Cosentino, F., Elisaf, M., Farnier, M., Ferrières, J., Filardi, P. P., Hâncu, N., et al. (2016) · European Heart Journal Supplements · doi:10.1093/eurheartj/suw009 · Cited by 97
Physical Activity and Lipoprotein Lipid Disorders
Berg, A., Frey, I., Baumstark, M. W., Halle, M., & Keul, J. (1994) · Sports Medicine · doi:10.2165/00007256-199417010-00002 · Cited by 96
Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of ApoA- and ApoB-containing lipoprotein families
Alaupovic, P. (1991) · Progress in Lipid Research · doi:10.1016/0163-7827(91)90008-s · Cited by 94
Self-citation
An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
Chan, D. C., Chen, M. M., Ooi, E. M. M., & Watts, G. F. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01678.x · Cited by 85
Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial
Otvos, J. D., SHALAUROVA, I. Y., Freedman, D. S., & Rosenson, R. S. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00544-5 · Cited by 88
Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure
Attman, P.-O., Alaupovic, P., Tavella, M. J., & Knight‐Gibson, C. (1996) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/11.1.63 · Cited by 86
Self-citation
The effects of saturated fat and n-6 polyunsaturated fat on postprandial lipemia and hemostatic activity
Saloma, V., Rasi, V., Pekkanen, J., Jauhiainen, M., Vahtera, E. M., Pietinen, P., KORHONEN, H. J., Kuulasmaa, K., & Ehnholm, C. (1993) · Atherosclerosis · doi:10.1016/0021-9150(93)90034-r · Cited by 84
Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in Type II diabetes
Gervaise, N., Garrigue, M. A., Lasfargues, G., & Lecomte, P. (2000) · Diabetologia · doi:10.1007/s001250051366 · Cited by 82
The concept of apolipoprotein-defined lipoprotein families and its clinical significance
Alaupovic, P. (2003) · Current Atherosclerosis Reports · doi:10.1007/s11883-003-0036-8 · Cited by 84
Self-citation
Apolipoprotein AIV Gene Variant S347 Is Associated With Increased Risk of Coronary Heart Disease and Lower Plasma Apolipoprotein AIV Levels
Wong, W.-M. R., Hawe, E., Li, L. K., Miller, G. J., Nicaud, V., Pennacchio, L. A., Humphries, S. E., & Talmud, P. J. (2003) · Circulation Research · doi:10.1161/01.res.0000069688.94567.7a · Cited by 84
The role of hypertriglyceridemia in atherosclerosis
Le, N., & Walter, M. F. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0006-7 · Cited by 79
Lipid lowering, regression, and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council meeting.
Gotto, A. (1995) · Circulation · doi:10.1161/01.cir.92.3.646 · Cited by 87
Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety
Kulik, A., & Ruel, M. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903188413 · Cited by 76
Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia
Campos, H., Perlov, D., Khoo, C., & Sacks, F. M. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31574-1 · Cited by 73
Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk
Onat, A., & Hergenç, G. (2010) · Metabolism · doi:10.1016/j.metabol.2010.04.018 · Cited by 72
ApoC-III gene polymorphisms and risk of coronary artery disease
Olivieri, O., Stranieri, C., Bassi, A., Zaia, B., Girelli, D., Pizzolo, F., Trabetti, E., Cheng, S., Grow, M. A., Pignatti, P. F., et al. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200145-jlr200 · Cited by 70
Is atherosclerosis caused by high cholesterol?
Ravnskov, U. (2002) · QJM · doi:10.1093/qjmed/95.6.397 · Cited by 68
Plasma Levels of HDL Subpopulations and Remnant Lipoproteins Predict the Extent of Angiographically-Defined Coronary Artery Disease in Postmenopausal Women
Lamon‐Fava, S., Herrington, D. M., Reboussin, D. M., Sherman, M., Horvath, K. V., Cupples, L. A., White, C. C., Demissie, S., Schaefer, E. J., & Asztalos, B. F. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.157123 · Cited by 67
The T Allele of the Hepatic Lipase Promoter Variant C−480T Is Associated With Increased Fasting Lipids and HDL and Increased Preprandial and Postprandial LpCIII:B
Jansen, H., Chu, G., Ehnholm, C., Dallongeville, J., Nicaud, V., & Talmud, P. J. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.2.303 · Cited by 68
Dyslipidemia of kidney disease
Attman, P., & Samuelsson, O. G. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832dd832 · Cited by 68
Associations Between Lipoproteins and the Progression of Coronary and Vein-Graft Atherosclerosis in a Controlled Trial With Gemfibrozil in Men With Low Baseline Levels of HDL Cholesterol
Syvänne, M., Nieminen, M. S., Frick, M. H., Kauma, H., Majahalme, S. K., Virtanen, V., Kesäniemi, Y. A., Pasternack, A. I., Ehnholm, C., & Taskinen, M. (1998) · Circulation · doi:10.1161/01.cir.98.19.1993 · Cited by 67
Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function
Båvenholm, P. (1998) · European Heart Journal · doi:10.1053/euhj.1997.0752 · Cited by 67
Apolipoprotein C‐III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation
Olivieri, O., Martinelli, N., Girelli, D., Pizzolo, F., Friso, S., Beltrame, F., Lotto, V., Annarumma, L., & Corrocher, R. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03720.x · Cited by 63
Alterations in plasma lipoproteins and apolipoproteins before the age of 40 in heterozygotes for lipoprotein lipase deficiency
Bijvoet, S. M., Gagné, S., Moorjani, S., Gagné, C., Henderson, H., Fruchart, J., Dallongeville, J., Alaupovic, P., Prins, M. H., Kastelein, J. J. P., et al. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37605-7 · Cited by 65
Self-citation
Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia
Cohn, J. S., Tremblay, M., Batal, R., Jacques, H., Rodriguez, C., Steiner, G. A., Mamer, O., & Davignon, J. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.06.011 · Cited by 62
Triglycerides as a risk factor for coronary artery disease
Sprecher, D. L. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00953-9 · Cited by 60
The compositional abnormalities of lipoproteins in diabetic renal failure
Attman, P.-O., Knight‐Gibson, C., Tavella, M. J., Samuelsson, O. G., & Alaupovic, P. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.11.2833 · Cited by 59
Self-citation
Retardation and arrest of progression or regression of coronary artery disease: A review
Vos, J., de Feyter, P. J., Simoons, M. L., Tijssen, J. G. P., & Deckers, J. W. (1993) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(93)90028-c · Cited by 57
Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease
Koren, E., Corder, C. N., Mueller, G., Centurion, H., Hallum, G., Fesmire, J., McConathy, W. D., & Alaupovic, P. (1996) · Atherosclerosis · doi:10.1016/0021-9150(95)05791-9 · Cited by 56
Self-citation
HDL and triglyceride as therapeutic targets
Fruchart, J., & Duriez, P. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200212000-00003 · Cited by 56
Serum apolipoprotein C‐III in high‐density lipoprotein: a key diabetogenic risk factor in Turks
Onat, A., Hergenç, G., Ayhan, E., Uğur, M., Kaya, H., Tuncer, M., & Can, G. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02814.x · Cited by 54
Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels
Alaupovic, P., Heinonen, T. M., Shurzinske, L., & Black, D. M. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)00119-6 · Cited by 54
Self-citation
Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: Estrogen in the Prevention of Atherosclerosis Trial
Karim, R., Mack, W. J., Lobo, R. A., Hwang, J., Liu, C., Liu, C.-H., Sevanian, A., & Hodis, H. N. (2005) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000153934.76086.a4 · Cited by 52
Complexities of plasma apolipoprotein C-III metabolism
Frank M. Sacks, E. B., Zheng, C., & Jeffrey S. Cohn, E. B. (2011) · Journal of Lipid Research · doi:10.1194/jlr.e015701 · Cited by 54
Atorvastatin Decreases Apolipoprotein C-III in Apolipoprotein B-Containing Lipoprotein and HDL in Type 2 Diabetes
Dallinga‐Thie, G. M., Berk-Planken, I. I. L., Bootsma, A. H., Jansen, H., & on behalf of the Diabetes Atorvastatin Lipid Intervention (DALI) Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1358 · Cited by 51
Associations of genotypes at the apolipoprotein AI‐CIII‐AIV, apolipoprotein B and lipoprotein lipase gene loci with coronary atherosclerosis and high density lipoprotein subclasses
Peacock, R. E., Hamsten, A., Johansson, J., Nilsson‐Ehle, P., & Humphries, S. E. (1994) · Clinical Genetics · doi:10.1111/j.1399-0004.1994.tb04159.x · Cited by 53
Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and “insulin-resistant” T-455C APOC3 gene polymorphism in heart disease patients: example of gene-diet interaction
Olivieri, O., Martinelli, N., Sandri, M., Bassi, A., Guarini, P., Trabetti, E., Pizzolo, F., Girelli, D., Friso, S., Pignatti, P. F., et al. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.040477 · Cited by 50

Authors: Blankenhorn, D. H., Alaupovic, P., Wickham, E., Chin, H. P., & Azen, S. P.
Affiliations: University of Southern California (US)
ORCID: Alaupovic, P
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1990-02
Volume: 81
Issue: 2
Pages: 470-476
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/01.cir.81.2.470
OpenAlex: W2092138949
Cited by: 278
References: 32
Citations by year: 2026: 1 · 2025: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 8 · 2016: 3 · 2015: 3 · 2014: 5 · 2013: 6 · 2012: 6
FWCI: 22.83
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Funders: Oklahoma Medical Research Foundation
National Institutes of Health (5p01hl023619-10)
National Heart, Lung, and Blood Institute (HL 23619)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: coronary artery disease progression, aortocoronary bypass graft, native coronary arteries, colestipol, nicotinic acid, cholesterol-lowering therapy, risk factors, non-HDL cholesterol, apolipoprotein C-III, HDL cholesterol, triglyceride-rich lipoproteins, apolipoprotein B, LDL cholesterol, triglycerides, diastolic blood pressure, atherosclerosis regression
MeSH terms: Coronary Artery Bypass, Apolipoproteins, Apolipoproteins C, Colestipol, Coronary Artery Disease, Humans, Lipids, Male, Middle Aged, Niacin, Recurrence, Multivariate Analysis, Randomized Controlled Trials as Topic, Coronary Angiography, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks